Allergy Therapeutics PLC Allergy Therapeutics shares data at WAO-BSACI
25 April 2022 - 4:01PM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
25 April 2022
Al l e r g y Th e r a p e u ti cs p l c
(" A l l e r gy T he r a peu t i cs", the "Group" or " C o m p a n y " )
Allergy Therapeutics shares positive data at the 2022 WAO-BSACI
Conference
25 April 2022 Allergy Therapeutics plc (AIM: AGY), the fully
integrated commercial biotechnology company specialising in allergy
vaccines, will share positive new data from across its research
portfolio at the joint WAO (World Allergy Organisation) & BSACI
( British Society for Allergy & Clinical Immunology) 2022 UK
Conference in Edinburgh, Scotland, from 25 to 27 April 2022.
Potential novel grass pollen immunotherapy
The first of the Group's posters presents findings from the
exploratory field study (G309) conducted to further optimise the
trial design of the upcoming pivotal Phase III clinical trial
(G306) investigating the Group's wholly owned short-course grass
pollen immunotherapy candidate, Grass MATA MPL. Data from the
study, conducted in the US and EU, show that the immunotherapy
demonstrated clinically relevant and statistically significant
reductions in the daily symptoms and the use of relief medications
after 6 subcutaneous allergen-specific immunotherapy (SCIT)
injections in two different treatment regimens. The results
highlight the potential of this novel, short-course immunotherapy
targeting grass pollen allergies and support the route to
registration in both Europe and the US.
Real-World-Evidence data of MCT(R)-associated allergoid SCIT
platform
Another poster reports on the Group's TARGET study.
Real-World-Evidence data are becoming increasingly important for
academia but also regulators. Real-World-Evidence allow insights
into the therapeutic effectiveness of a drug but also disease
modification and or long-term effectiveness of allergen
immunotherapy (AIT). The aim of the "Tyrosine Allergoid Real World
Evidence in Germany Effectiveness in AIT" (TARGET) study was to
demonstrate the long-term benefit of MCT(R) -associated allergoid
SCIT in routine clinical practice. The progression of allergic
rhinitis (AR) and asthma was measured in patients receiving one of
three allergoid SCIT in comparison to matched control groups
without AIT using prescription data of more than 181,000 German
patients within the statutory health insurance system based on the
IMS(R) LRx database (IQVIA, Germany). The TARGET study demonstrated
long-term benefits of allergoid SCIT including MCT(R)-associated
allergoids on AR and asthma up to 9.5 years (Ø 6.3 years) of follow
up in routine clinical practice.
The hypo-allergic potential of VLP Peanut against peanut
exposure
The latest pre-clinical mechanistic data on Allergy
Therapeutics' peanut vaccine candidate, VLP Peanut, will also be
showcased in a poster which illustrates how a vaccine incorporating
the major peanut allergen (recombinant Ara h 2) has the potential
to protect against all peanut allergens. The mouse anaphylaxis
model of peanut allergy demonstrated that the vaccine candidate
exhibited a non-reactogenic profile after intravenous challenge
with whole peanut extract. This result further supports the
hypo-allergic potential of VLP Peanut, in alignment with the
results previously demonstrated using human blood cells, which is a
vital quality in delivering a viable peanut allergy vaccine.
Additional data being presented show that a single dose of VLP
Peanut protected mice against anaphylaxis in a peanut sensitized
mouse model. The upcoming Phase I PROTECT trial, the first human
study exploring the potential of this peanut vaccine candidate will
begin later in 2022, following FDA clearance of the Group's IND
application, with topline data expected in 2023.
The posters will be presented at the WAO & BSACI UK
Conference on Tuesday 26 April between 11:05 - 14:00 (BST)
https://wao-bsaci.org/ . Abstracts of each will be made available
on the Company website.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company focussed on the treatment and diagnosis of
allergic disorders, including aluminium free immunotherapy vaccines
that have the potential to cure disease. The Group sells
proprietary and third-party products from its subsidiaries in nine
major European countries and via distribution agreements in an
additional ten countries. Its broad pipeline of products in
clinical development includes vaccines for grass, tree and house
dust mite, and peanut allergy vaccine in pre-clinical development.
Adjuvant systems to boost performance of vaccines outside allergy
are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group employs c.600 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com .
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAKZLFLLZLZBBZ
(END) Dow Jones Newswires
April 25, 2022 02:01 ET (06:01 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024